MYCO-002
MYCO-002 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
MYCO-002 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders. It is said to be being developed towards the aim of improving the safety profile of MDMA. The drug is under development by Mydecine.
It was patented in July 2021 and received breakthrough therapy designation from the Food and Drug Administration (FDA) in November 2021. As of November 2021, MYCO-002 is in the preclinical research for treatment of psychiatric disorders. The chemical structure of MYCO-002 does not yet appear to have been disclosed.
See also
MYCO-006 MYCO-007 List of investigational hallucinogens and entactogens
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372023197 under CC BY-SA 4.0; modifications have been made.